Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

725 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Response to: 'Let's stop fooling ourselves. In RA, only ACR/EULAR criteria define remission and equate with absence of disease!' by Boers.
Emery P, Bingham CO 3rd, Burmester GR, Bykerk VP, Furst DE, Mariette X, Heijde Dv, Vollenhoven Rv, Arendt C, Mountian I, Purcaru O, Tatla D, VanLunen B, Weinblatt ME. Emery P, et al. Among authors: furst de. Ann Rheum Dis. 2016 Oct;75(10):e69. doi: 10.1136/annrheumdis-2016-210083. Epub 2016 Aug 12. Ann Rheum Dis. 2016. PMID: 27519773 Free article. No abstract available.
Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.
Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, Weaver AL, Keystone EC, Furst DE, Mease PJ, Ruderman EM, Horwitz DA, Arkfeld DG, Garrison L, Burge DJ, Blosch CM, Lange ML, McDonnell ND, Weinblatt ME. Moreland LW, et al. Among authors: furst de. Ann Intern Med. 1999 Mar 16;130(6):478-86. doi: 10.7326/0003-4819-130-6-199903160-00004. Ann Intern Med. 1999. PMID: 10075615 Clinical Trial.
Access to disease modifying treatments for rheumatoid arthritis patients.
Furst DE, Breedveld FC, Burmester GR, Crofford L, Emery P, Feldman M, Kalden JR, Kavanaugh A, Keystone E, Lipsky PE, Maini RN, Moreland L, Smolen JS, Van De Putte L, Vischer T, Weinblatt M, Weissman M. Furst DE, et al. Ann Rheum Dis. 1999 Nov;58 Suppl 1(Suppl 1):I129-30. doi: 10.1136/ard.58.2008.i129. Ann Rheum Dis. 1999. PMID: 10577989 Free PMC article. Review. No abstract available.
Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.
Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P. Maini R, et al. Lancet. 1999 Dec 4;354(9194):1932-9. doi: 10.1016/s0140-6736(99)05246-0. Lancet. 1999. PMID: 10622295 Clinical Trial.
Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis (May 2000).
Furst DE, Breedveld FC, Burmester GR, Crofford JJ, Emery P, Feldmann M, Kalden JR, Kavanaugh AF, Keystone EC, Klareskog LG, Lipsky PE, Maini RN, Russell AS, Scott DL, Smolen JS, Van de Putte LB, Visher TL, Weisman MH. Furst DE, et al. Ann Rheum Dis. 2000 Nov;59 Suppl 1(Suppl 1):i1-2. doi: 10.1136/ard.59.suppl_1.i1. Ann Rheum Dis. 2000. PMID: 11053077 Free PMC article. Review. No abstract available.
725 results